Open AccessInfluence of CFH, HTRA1 and ARMS2 polymorphisms in the response to intravitreal ranibizumab treatment for wet age-related macular degeneration in a Spanish population
Author(s) -
Fernando Cruz-González,
L. Cabrillo-Estévez,
Vanesa Rivero-Gutiérrez,
Ana Sanchez-Jara,
Lourdes de Juan-Marcos,
Rogelio GonzálezSarmiento
Publication year - 2016
Publication title -
international journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.634
H-Index - 29
eISSN - 2227-4898
pISSN - 2222-3959
DOI - 10.18240/ijo.2016.09.12
Subject(s) - ranibizumab , medicine , macular degeneration , factor h , ophthalmology , visual acuity , choroidal neovascularization , taqman , polymerase chain reaction , immunology , gene , genetics , complement system , bevacizumab , chemotherapy , immune system , biology
To determine whether gene polymorphisms of the major genetic risk loci for age-related macular degeneration (AMD): ARMS2 (rs10490923), the complement factor H (CFH) (rs1410996) and HTRA1 (rs11200638) influence the response to a treatment regimen with ranibizumab for exudative AMD.